# A Study on the Efficacy and Safety of Long-Term Treatment and Re-Treatment of Lower Extremity Diabetic Ulcers With REGRANEX

> **NCT00034788** · PHASE3 · TERMINATED · sponsor: **Johnson & Johnson Pharmaceutical Research & Development, L.L.C.** · enrollment: 84 (actual)

## Conditions studied

- Foot Ulcer
- Diabetic Foot
- Skin Ulcer
- Diabetic Neuropathies

## Interventions

- **DRUG:** Becaplermin

## Key facts

- **NCT ID:** NCT00034788
- **Lead sponsor:** Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2000-12
- **Primary completion:** —
- **Final completion:** 2004-02
- **Target enrollment:** 84 (ACTUAL)
- **Why stopped:** Slow recruitment; Study did not address safety concern raised by European Medicines Agency
- **Last updated:** 2011-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00034788

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00034788, "A Study on the Efficacy and Safety of Long-Term Treatment and Re-Treatment of Lower Extremity Diabetic Ulcers With REGRANEX". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00034788. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*